Paul R. Kirchgraber - Feb 7, 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Stock symbol
LH
Transactions as of
Feb 7, 2023
Transactions value $
$0
Form type
4
Date filed
2/9/2023, 11:02 AM
Previous filing
Feb 7, 2023
Next filing
Feb 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LH Restricted Stock Unit Award $0 +1.59K +83.95% $0.00 3.48K Feb 7, 2023 Common Stock 1.59K Direct F1, F2, F3
transaction LH Non-qualified Stock Options Award $0 +5K $0.00 5K Feb 7, 2023 Common Stock 5K $247.24 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2 The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024.
F3 This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
F4 Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
F5 The option vests in three equal annual installments beginning on the date reflected in this column.